Evercore ISI Lowers ICON Public (NASDAQ:ICLR) Price Target to $330.00

ICON Public (NASDAQ:ICLR) had its target price decreased by equities research analysts at Evercore ISI from $350.00 to $330.00 in a report released on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s target price points to a potential upside of 7.04% from the stock’s previous close.

Several other analysts have also weighed in on the company. Truist Financial increased their price target on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Barclays upped their price objective on ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Robert W. Baird upped their price objective on ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a research report on Friday. TD Cowen upped their price objective on ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research report on Friday. Finally, Mizuho reaffirmed a “buy” rating and issued a $346.00 price objective on shares of ICON Public in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, ICON Public currently has an average rating of “Moderate Buy” and a consensus target price of $321.64.

ICON Public Stock Performance

NASDAQ:ICLR opened at $308.31 on Friday. The stock’s fifty day moving average is $318.89 and its 200 day moving average is $283.09. ICON Public has a fifty-two week low of $181.92 and a fifty-two week high of $344.77. The firm has a market capitalization of $25.44 billion, a PE ratio of 37.51, a PEG ratio of 1.42 and a beta of 1.15. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.08 billion. On average, sell-side analysts anticipate that ICON Public will post 14.4 earnings per share for the current year.

Hedge Funds Weigh In On ICON Public

Hedge funds and other institutional investors have recently made changes to their positions in the company. Liontrust Investment Partners LLP grew its position in shares of ICON Public by 108.4% during the 3rd quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after buying an additional 46,739 shares in the last quarter. Chartwell Investment Partners LLC grew its position in shares of ICON Public by 16.1% during the 3rd quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock worth $1,712,000 after buying an additional 963 shares in the last quarter. Whittier Trust Co. grew its position in shares of ICON Public by 6.2% during the 4th quarter. Whittier Trust Co. now owns 2,702 shares of the medical research company’s stock worth $765,000 after buying an additional 158 shares in the last quarter. Cullen Investment Group LTD. bought a new position in shares of ICON Public during the 4th quarter worth $1,620,000. Finally, Prime Capital Investment Advisors LLC purchased a new stake in shares of ICON Public during the 4th quarter worth $416,000. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.